Apogee Therapeutics, Inc. (APGE)
Health Care ยท Biological Products, (No Diagnostic Substances)
Apogee Therapeutics, Inc. (APGE) was listed on Nasdaq from July 14, 2023. SentiSense covers Apogee Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Michael Henderson is its chief executive officer. The company reports 261 employees, and its corporate website is www.apogeetherapeutics.com.
About Apogee Therapeutics, Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Latest reported results
Apogee Therapeutics reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 279 institutions reported holding APGE, with 67.5 million shares worth $8.9 billion in aggregate. The largest reported holders were VR Adviser, BlackRock and Vanguard.
More on APGE
- APGE sentiment: whether news and social coverage of Apogee Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- APGE ownership: all 279 reporting institutions, plus insider and congressional trades.
- APGE financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
Frequently asked questions
What does Apogee Therapeutics, Inc. do?
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. .
What sector is APGE in?
SentiSense classifies Apogee Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where did APGE stock trade?
Apogee Therapeutics, Inc. (APGE) was listed on Nasdaq from July 14, 2023.
Who is the CEO of Apogee Therapeutics, Inc.?
Michael Henderson is the chief executive officer of Apogee Therapeutics, Inc..